Healthcare

Cynata Therapeutics Limited (ASX:CYP)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.630.02 (3.279%)

(as on 2021-10-17 09:55:21)

Market Cap : AUD 90.264 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.61 0.61 0.63 0.61L 0.635 H 0.47L 0.9272321429 H
Last Trade 0.63
Change% 3.2787
52 W H/L 0.9272321429/0.47
EBITDA -8.116 M
NPAT After Abnormal Items -7.69 M
Equity 28.373 M
ROE% -27.10%
Total Liabilities 1.602 M
Total Revenue 1.596 M
Cash and Cash Equivalents 26.717 M

Stock Information

Share price 0.63
Market Cap 90.264 M
Price/Gross Cash Flow -14.00
Dividend Yield Excluding Special 0.00%
Ending Shares 143.277 M
52-Week Range 0.47-0.9272321429
P/E ratio 0.000
Sector P/E --
EPS -5.90
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.04
Net Gearing -94.16%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.18
Sales Per Share 0.00
Book Value Per Share 0.20

Announcements

Heading Date/Time
Annual Report to shareholders  14/10/2021 5:17PM
Letter to Shareholders & Notice of Annual General Meeting  14/10/2021 5:07PM
Notification regarding unquoted securities - CYP  12/10/2021 5:13PM
DSMB Recommends Continuation of Cynata's MEND Trial  08/10/2021 9:23AM
Cynata Enters into a New Strategic Partnership with Fujifilm  30/09/2021 2:02PM
CYP Preclinical Heart Attack Study Published in Cytotherapy  28/09/2021 9:29AM
Date of AGM and Closing Date for Director Nominations  21/09/2021 4:48PM
Further Patents for Cynata Unique Cymerus Technology  15/09/2021 12:38PM
Further Canadian Patent for Cynata  31/08/2021 9:00AM
Appendix 4G  30/08/2021 12:56PM
Appendix 4E & Annual Report  30/08/2021 12:55PM
Cynata Receives Notice of Allowance from US Patent Office  26/08/2021 1:24PM
Quarterly Activity Report & Appendix 4C  28/07/2021 9:07AM
Cynata Appoints Dr Jolanta Airey Chief Medical Officer  26/07/2021 11:19AM
Change of Registered Office  05/07/2021 5:35PM
Ethics Approval for Cynata's Clinical Trial in DFU  30/06/2021 9:49AM
Progress Toward Clinical Trial in Diabetic Foot Ulcers  28/06/2021 9:20AM
Cynata to Present at MST Access Investor Conference 15 June  11/06/2021 2:41PM
Cynata signs Licence Agreement with TekCyte  03/06/2021 11:09AM
Release of Securities from Voluntary Escrow  28/05/2021 5:38PM
First Patient Enrolled in Cynata MEND Clinical Trial  24/05/2021 12:10PM
Quarterly Activity Report & Appendix 4C  28/04/2021 9:15AM
Cynata Expands trial in COVID-19 & Respiratory Failure  29/03/2021 9:43AM
Cynata Investor Presentation  12/03/2021 9:14AM
New Study to Investigate the High Potency of Cymerus MSCs  02/03/2021 9:21AM
Cynata Advances Planned Clinical Trial in DFU with TekCyte  01/03/2021 9:15AM
Appendix 4D & Half-Year Financial Statements  25/02/2021 5:55PM
Cynata Receives $1.39m R&D Tax Incentive Refund  22/02/2021 9:15AM
Quarterly Activity Report & Appendix 4C  29/01/2021 9:29AM

Similar Companies

Related Articles

Load More

About Company

CYNATA THERAPEUTICS LIMITED (ASX: CYP) is into regenerative stem cell and medicine development under the healthcare segment. The company was listed in 2007 and is based in Lygon Street, Carlton, Australia. It has Cymerus™ Mesenchymal Stem Cell product that is effective in Diabetes.

Corporate Information

company address Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053

company phone(03) 9824 5254

company websitehttp://www.cynata.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-10-13 2022
Report (Annual) 2022-08-29 2022
Report (Prelim) 2022-08-29 2022
Report (Interim) 2022-02-24 2022
Report (Annual) 2021-10-22 2021

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- -- -- -- --
Other Revenue 1.596 M 7.012 M 1.328 M 1.375 M 1.749 M
Total Revenue 1.596 M 7.012 M 1.328 M 1.375 M 1.749 M
Interest Income 92,299 142,350 260,551 142,925 94,231
Interest Expenses 0 0 0 0 0
Expenses -9.098 M -10.512 M -9.781 M -5.804 M -6.117 M
EBITDA -7.502 M -3.501 M -8.453 M -4.429 M -4.368 M
Depreciation and Amortization -279,965 -280,732 -279,965 -279,965 -279,965
Depreciation 0 0 0 0 0
Amortisation -279,965 -280,732 -279,965 -279,965 -279,965
EBIT -7.782 M -3.781 M -8.733 M -4.709 M -4.648 M
Pre Tax Profit -7.69 M -3.639 M -8.472 M -4.566 M -4.554 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -7.69 M -3.639 M -8.472 M -4.566 M -4.554 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 0 0
Reported Net Profit After Abnormal Items -7.69 M -3.639 M -8.472 M -4.566 M -4.554 M
Ending Shares 143.277 M 117.476 M 102.192 M 95.352 M 90.328 M
Weighted Average Shares 130.427 M 104.825 M 100.214 M 90.882 M 80.302 M
EPS After Abnormal Items (cents) -5.9 -3.47 -8.45 -5.02 -5.67
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 27.282 M 13.851 M 7.33 M 12.6 M 10.441 M
Total Non Current Assets 2.693 M 3.63 M 4.919 M 3.533 M 3.813 M
Total Assets 29.975 M 17.481 M 12.25 M 16.133 M 14.254 M
Total Current Liabilities 1.602 M 689,736 1.278 M 746,146 389,597
Total Non Current Liabilities 0 0 0 0 0
Total Liabilities 1.602 M 689,736 1.278 M 746,146 389,597
Net Assets 28.373 M 16.791 M 10.971 M 15.387 M 13.865 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -5.163 M -3.388 M -6.759 M -4.062 M -4.048 M
Net Invested Cash 0 0 0 0 0
Net Financing Cash Flows 18.197 M 10.06 M 1.53 M 5.858 M 9.586 M
Beginning Cash 13.65 M 6.977 M 12.206 M 10.35 M 4.879 M
End Cash Position 26.717 M 13.65 M 6.977 M 12.206 M 10.35 M
Exchange Rate Adjustments 33,002 -15 12 59,779 -67,218
Other Cash Adjustments 0 0 0 0 0
Ending Cash 26.717 M 13.65 M 6.977 M 12.206 M 10.35 M

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK